Literature DB >> 11693508

Epidemiology of varicella zoster virus infection in Canada and the United Kingdom.

M Brisson1, W J Edmunds, B Law, N J Gay, R Walld, M Brownell, L L Roos, L Roos, G De Serres.   

Abstract

Many countries are currently studying the possibility of mass vaccination against varicella. The objective of this study was to provide a comprehensive picture of the pre-vaccine epidemiology of the varicella zoster virus (VZV) to aid in the design of immunization programs and to adequately measure the impact of vaccination. Population-based data including physician visit claims, sentinel surveillance and hospitalization data from Canada and the United Kingdom were analysed. The key epidemiological characteristics of varicella and zoster (age specific consultation rates, seasonality, force of infection, hospitalization rates and inpatient days) were compared. Results show that the overall epidemiology of varicella and zoster is remarkably similar between the two countries. The major difference being that, contrary to Canada, the epidemiology of varicella seems to be changing in the United Kingdom with an important decrease in the average age at infection that coincides with a significant increase in children attending preschool. Furthermore, differences exist in the seasonality between the United Kingdom and Canada, which seem to be primarily due to the school calendar. These results illustrate that school and preschool contact patterns play an important role in the dynamics of varicella. Finally, our results provide baseline estimates of varicella and zoster incidence and morbidity for VZV vaccine effectiveness and cost-effectiveness studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11693508      PMCID: PMC2869750          DOI: 10.1017/s0950268801005921

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  117 in total

1.  Deaths from chickenpox. Deaths from chickenpox in adults are decreasing.

Authors:  Marc Brisson; W John Edmunds; Nigel J Gay; Elizabeth Miller
Journal:  BMJ       Date:  2002-03-09

2.  The incidence of chickenpox in the community. Lessons for disease surveillance in sentinel practice networks.

Authors:  D M Fleming; F G Schellevis; I Falcao; T V Alonso; M L Padilla
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

3.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.

Authors:  Mélanie Drolet; Marc Brisson; Kenneth E Schmader; Myron J Levin; Robert Johnson; Michael N Oxman; David Patrick; Caty Blanchette; James A Mansi
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

Review 4.  Annual adult health checkup: update on the Preventive Care Checklist Form(©).

Authors:  Anthony Duerksen; Vinita Dubey; Karl Iglar
Journal:  Can Fam Physician       Date:  2012-01       Impact factor: 3.275

5.  Zoster vaccination: A new opportunity for adult immunization.

Authors:  Kevin B Laupland; David N Fisman
Journal:  Can J Infect Dis Med Microbiol       Date:  2009       Impact factor: 2.471

6.  Vaccination boosts adult immunity to varicella zoster virus.

Authors:  Erica Weir
Journal:  CMAJ       Date:  2005-08-02       Impact factor: 8.262

Review 7.  Chickenpox, chickenpox vaccination, and shingles.

Authors:  P D Welsby
Journal:  Postgrad Med J       Date:  2006-05       Impact factor: 2.401

8.  Secular trends in the epidemiology of shingles in Alberta.

Authors:  M L Russell; D P Schopflocher; L Svenson; S N Virani
Journal:  Epidemiol Infect       Date:  2007-02-12       Impact factor: 2.451

9.  The burden of disease of Herpes Zoster in Tuscany.

Authors:  Miriam Levi; Irene Bellini; Leonardo Capecchi; Luca Pieri; Angela Bechini; Sara Boccalini; Silvia Callaioli; Roberto Gasparini; Donatella Panatto; Emilia Tiscione; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

10.  Cost effectiveness of herpes zoster vaccine in Canada.

Authors:  Mehdi Najafzadeh; Carlo A Marra; Eleni Galanis; David M Patrick
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.